Literature DB >> 8580930

A useful testing strategy in phase III trials: combined test of superiority and test of equivalence.

T Morikawa1, M Yoshida.   

Abstract

A useful testing strategy is proposed for a confirmatory phase III clinical trial. It consists of a combined test of superiority and test of equivalence, and it is easy to apply. By introducing the strategy, we can perform a post hoc analysis in a confirmatory experiment. Thus a more flexible decision will be possible than the usual single testing method provides. It is shown that the procedure needs no adjustment for multiplicity from the point of view of the closed testing procedure. The relationship between this strategy and a confidence interval is also discussed.

Mesh:

Year:  1995        PMID: 8580930     DOI: 10.1080/10543409508835115

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  11 in total

1.  Equivalence concepts in clinical trials.

Authors:  V W Steinijans; M Neuhäuser; F Bretz
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jan-Mar       Impact factor: 2.441

2.  Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial.

Authors:  Desmond Curran; Carmelo Pozzo; Jerzy Zaluski; Magdalena Dank; Carlo Barone; Vahur Valvere; Suayib Yalcin; Christian Peschel; Miklós Wenczl; Erdem Goker; Roland Bugat
Journal:  Qual Life Res       Date:  2009-07-01       Impact factor: 4.147

3.  A randomised, double masked, multicentre clinical trial comparing bimatoprost and timolol for the treatment of glaucoma and ocular hypertension.

Authors:  S M Whitcup; L B Cantor; A M VanDenburgh; K Chen
Journal:  Br J Ophthalmol       Date:  2003-01       Impact factor: 4.638

Review 4.  Rationale for and methods of superiority, noninferiority, or equivalence designs in orthopaedic, controlled trials.

Authors:  Patrick Vavken
Journal:  Clin Orthop Relat Res       Date:  2011-01-19       Impact factor: 4.176

5.  Clinical study to evaluate the safety and effectiveness of the Aesculap Activ-L artificial disc in the treatment of degenerative disc disease.

Authors:  James J Yue; Fred F Mo
Journal:  BMC Surg       Date:  2010-04-09       Impact factor: 2.102

6.  The USA Multicenter Prehosptial Hemoglobin-based Oxygen Carrier Resuscitation Trial: scientific rationale, study design, and results.

Authors:  Ernest E Moore; Jeffrey L Johnson; Frederick A Moore; Hunter B Moore
Journal:  Crit Care Clin       Date:  2009-04       Impact factor: 3.598

7.  Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial.

Authors:  David Ferry; Lucinda Billingham; Hugh Jarrett; David Dunlop; Penella J Woll; Marianne Nicolson; Riyaz Shah; Joyce Thompson; James Spicer; D Muthukumar; Geraldine Skailes; Pauline Leonard; A D Chetiyawardana; Paula Wells; Conrad Lewanski; Barbara Crosse; Michelle Hill; Piers Gaunt; Kenneth O'Byrne
Journal:  Eur J Cancer       Date:  2017-08-04       Impact factor: 9.162

8.  Non-inferiority versus superiority drug claims: the (not so) subtle distinction.

Authors:  Jitendra Ganju; Dror Rom
Journal:  Trials       Date:  2017-06-15       Impact factor: 2.279

9.  Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial.

Authors:  P C Bartley; M Bogoev; J Larsen; A Philotheou
Journal:  Diabet Med       Date:  2008-04       Impact factor: 4.359

10.  A randomized, controlled, multicentre clinical trial of post-extraction alveolar ridge preservation.

Authors:  Eric Todd Scheyer; Rick Heard; Jim Janakievski; George Mandelaris; Marc L Nevins; Stephen R Pickering; Christopher R Richardson; Bryan Pope; Gregory Toback; Diego Velásquez; Heiner Nagursky
Journal:  J Clin Periodontol       Date:  2016-10-21       Impact factor: 8.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.